Ticagrelor

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

Retrieved on: 
Friday, January 26, 2024
Pomerantz, Patient, LLP, Cytosorbents Corporation, Ticagrelor, AstraZeneca, News, ATR

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).

Key Points: 
  • NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).
  • The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

Retrieved on: 
Thursday, January 18, 2024
Pomerantz, Patient, LLP, Prior, Cytosorbents Corporation, Ticagrelor, AstraZeneca, News, ATR

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).

Key Points: 
  • NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).
  • The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

Retrieved on: 
Wednesday, January 10, 2024
Pomerantz, Patient, LLP, Cytosorbents Corporation, Ticagrelor, AstraZeneca, News, ATR

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).

Key Points: 
  • NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).
  • The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, January 9, 2024
Telephone, Patient, Ticagrelor, ATR, P.C, AstraZeneca, News

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO) on behalf of Cytosorbents stockholders.

Key Points: 
  • NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO) on behalf of Cytosorbents stockholders.
  • Our investigation concerns whether Cytosorbents has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • On this news, Cytosorbents' stock price fell $0.545 per share, or 33.44%, to close at $1.085 per share on December 28, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

Retrieved on: 
Tuesday, January 2, 2024
AstraZeneca, LLP, News, Pomerantz, Prior, Cytosorbents Corporation, Patient, Ticagrelor, ATR

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).

Key Points: 
  • NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).
  • The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

Retrieved on: 
Wednesday, September 27, 2023
CABG, Percutaneous coronary intervention, Anticoagulant, International, Bleeding, Intraparenchymal hemorrhage, CET, Boehringer, Dabigatran, STAR, EACTS, Edoxaban, Acute coronary syndrome, International Star Registry, Cytokine adsorbing column, CTD, Research, AstraZeneca, Professional corporation, Eli Lilly, Clopidogrel, DOAC, Boehringer Ingelheim, Incidence, Bayer, Neurosurgery, International Safe Harbor Privacy Principles, Patient, Risk, European Heart Journal, Daiichi Sankyo, Blood, Rivaroxaban, Annual general meeting, Cytosorbents Corporation, United Kingdom, BMS, Cardiology, European Association for Cardio-Thoracic Surgery, Starship Enterprise, Trauma, Ticagrelor, ATR, Pfizer, Birth control, Pharmaceutical industry, Dentistry, Janssen, Aorta, Sanofi

The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.

Key Points: 
  • The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.
  • The STAR Registry, not to be confused with the completed U.S. and Canada STAR-T pivotal trial, is enrolling ahead of internal projections with plans for ongoing presentations at large, international conferences.
  • The first registry analysis entitled, “ Insights from the International Safe and Timely Antithrombotic Removal (STAR) Registry ” was presented at the EuroPCR conference in May 2023, the largest interventional cardiology conference in the E.U., attracting 11,500+ participants this year.
  • It also includes, for the first time, data on patients being treated with CytoSorb to reduce seven different antithrombotic medications.

SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics

Retrieved on: 
Thursday, July 13, 2023
Epilepsy, Neutropenia, Infection, Central nervous system, Emergency, Capecitabine, Urine, SERB, Severe cutaneous adverse reactions, Toxicity, Megaloblastic anemia, Patient, HOA, Orotic aciduria, Therapy, Ticagrelor, News, Biomatrix systems theory, Pharmaceutical industry

West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics.

Key Points: 
  • West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics.
  • [iii]
    Jeremie Urbain, President of SERB Pharmaceuticals, said: “We’re proud to add these two treatments to our expanding portfolio of medicines for complex, life-threatening conditions.
  • BTG Pharmaceuticals, a SERB company, will promote Vistogard® and continue promoting Voraxaze® through its oncology field force in the US.
  • Today’s news follows the announcement in May that SERB has acquired the exclusive US rights to bentracimab, which is in development as a ticagrelor reversal agent.

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Retrieved on: 
Friday, July 7, 2023
CABG, Bleeding, Hospital, Data collection, DRS, Attention, AstraZeneca, Professional corporation, U.S. FDA, Patient, Risk, Rivaroxaban, Cytosorbents Corporation, FDA, Health Canada, Pharmaceutical industry, Ticagrelor

Michael Mack, C. Michael Gibson, and Richard Whitlock, commented in a joint statement, “We want to thank all participating investigators and their research teams for their commitment and dedication that helped STAR-T complete enrollment ahead of projections.

Key Points: 
  • Michael Mack, C. Michael Gibson, and Richard Whitlock, commented in a joint statement, “We want to thank all participating investigators and their research teams for their commitment and dedication that helped STAR-T complete enrollment ahead of projections.
  • Ticagrelor (Brilinta®, AstraZeneca) is used widely in the U.S. and Canada and we routinely encounter patients on ticagrelor who require cardiothoracic surgery.
  • The surgical community is in urgent need of a solution that allows the safe and timely treatment of these high-risk patients.
  • The fast enrollment pace was the direct result of the high frequency that eligible patients presented at our participating sites validating the large size of the unmet need.

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

Retrieved on: 
Thursday, June 15, 2023
CABG, DSMB, AstraZeneca, Professional corporation, U.S. FDA, Data monitoring committee, Data, Patient, Risk, Cytosorbents Corporation, FDA, Health Canada, Pharmaceutical industry, Ticagrelor

Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents commented, “We would like to thank the independent DSMB for the prompt review of the full unblinded dataset from the first 80 patients enrolled in the STAR-T trial.

Key Points: 
  • Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents commented, “We would like to thank the independent DSMB for the prompt review of the full unblinded dataset from the first 80 patients enrolled in the STAR-T trial.
  • We are very pleased with the recommendation to continue the study as planned without modifications that now allows us to push towards the finish line in an expedited fashion.
  • Brilinta is one of the leading “blood thinners” used as part of dual-antiplatelet therapy in patients suspected of having a heart attack.
  • Waiting in the hospital to wash out the drug is the only acceptable alternative, but this comes at high cost and potential clinical risk.

SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent

Retrieved on: 
Thursday, May 11, 2023
Biologics license application, US Foods, Bleeding, Acute coronary syndrome, SERB, The New England Journal of Medicine, Stroke, CAD, Breakthrough therapy, SFJ, AstraZeneca, Ticagrelor, Bentracimab, Acquisition, Patient, Physician, Risk, SAN, Coronary artery disease, FDA, Death, BLA, Food, Pharmaceutical industry

PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ.

Key Points: 
  • PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ.
  • Bentracimab is a novel, monoclonal antibody fragment designed to reverse the antiplatelet activity of ticagrelor.
  • Ticagrelor, marketed by AstraZeneca as Brilinta®, is a reversible oral P2Y12 platelet inhibitor for patients who have suffered a heart attack or stroke, or who have acute coronary syndromes or coronary artery disease (CAD).
  • Leopoldo Zambeletti acted as advisor for SFJ, and Evercore acted as advisor for SERB.